Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Cherrie Galletly. (2014) Role of cognitive enhancement in schizophrenia. Neuroscience and Neuroeconomics 3, pages 75-85.
Read now
Read now
Andrea Gogos, Nicole Joshua & Susan L. Rossell. (2010) Use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to investigate group and gender differences in schizophrenia and bipolar disorder. Australian and New Zealand Journal of Psychiatry 44:3, pages 220-229.
Read now
Read now
Elizabeth Scarr & Brian Dean. (2009) Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Review of Neurotherapeutics 9:1, pages 73-86.
Read now
Read now
Articles from other publishers (31)
Yash B. Joshi. 2023. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework
393
406
.
Cassandra J. Hatzipantelis, Monica Langiu, Teresa H. Vandekolk, Tracie L. Pierce, Jess Nithianantharajah, Gregory D. Stewart & Christopher J. Langmead. (2020) Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. ACS Pharmacology & Translational Science 3:6, pages 1042-1062.
Crossref
Crossref
Ragy R. Girgis, Anthony W. Zoghbi, Daniel C. Javitt & Jeffrey A. Lieberman. (2019) The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research 108, pages 57-83.
Crossref
Crossref
Borja Santos, Eduardo González-Fraile, Arantzazu Zabala, Virginia Guillén, José R Rueda & Javier Ballesteros. (2018) Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. Journal of Psychopharmacology 32:11, pages 1155-1166.
Crossref
Crossref
Wen-Yu Hsu, Hsien-Yuan Lane & Chieh-Hsin Lin. (2018) Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease. Frontiers in Psychiatry 9.
Crossref
Crossref
PattathNarayanan Suresh Kumar, SeemaP Mohemmedali, PK Anish & Chittaranjan Andrade. (2017) Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. Indian Journal of Psychiatry 59:2, pages 219.
Crossref
Crossref
Saeed Shoja Shafti & Abbas Azizi Khoei. (2016) Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Therapeutic Advances in Psychopharmacology 6:5, pages 308-316.
Crossref
Crossref
Jayant Bhandari, Ritesh Daya & Ram K. Mishra. (2016) Improvements and important considerations for the 5-choice serial reaction time task—An effective measurement of visual attention in rats. Journal of Neuroscience Methods 270, pages 17-29.
Crossref
Crossref
M. Hvoslef-Eide, A. C. Mar, S. R. O. Nilsson, J. Alsiö, C. J. Heath, L. M. Saksida, T. W. Robbins & T. J. Bussey. (2015) The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia. Psychopharmacology 232:21-22, pages 3853-3872.
Crossref
Crossref
Annabel Vreeker, Annet H. van Bergen & René S. Kahn. (2015) Cognitive enhancing agents in schizophrenia and bipolar disorder. European Neuropsychopharmacology 25:7, pages 969-1002.
Crossref
Crossref
JW Young & MA Geyer. (2014) Developing treatments for cognitive deficits in schizophrenia: The challenge of translation. Journal of Psychopharmacology 29:2, pages 178-196.
Crossref
Crossref
M. Hvoslef-Eide, S. R. O. Nilsson, L. M. Saksida & T. J. Bussey. 2016. Translational Neuropsychopharmacology. Translational Neuropsychopharmacology
423
447
.
Lewis A. Opler, Alice Medalia, Mark G. Opler & Stephen M. Stahl. (2013) Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectrums 19:2, pages 142-156.
Crossref
Crossref
J W Young, M A Geyer, A J Rissling, R F Sharp, L T Eyler, G L Asgaard & G A Light. (2013) Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Translational Psychiatry 3:11, pages e324-e324.
Crossref
Crossref
Timothy J. Bussey, Deanna M. Barch & Mark G. Baxter. (2013) Testing long-term memory in animal models of schizophrenia: Suggestions from CNTRICS. Neuroscience & Biobehavioral Reviews 37:9, pages 2141-2148.
Crossref
Crossref
Jared W. Young, J. David Jentsch, Timothy J. Bussey, Tanya L. Wallace & Daniel M. Hutcheson. (2013) Consideration of species differences in developing novel molecules as cognition enhancers. Neuroscience & Biobehavioral Reviews 37:9, pages 2181-2193.
Crossref
Crossref
Mary Pipan, Paul P. Wang & Rebecca Thompson Penna. 2013. Pediatric Drug Development. Pediatric Drug Development
355
382
.
Joseph I. Friedman, Isabella Kanellopoulou & Vladan Novakovic. 2012. Targets and Emerging Therapies for Schizophrenia. Targets and Emerging Therapies for Schizophrenia
295
318
.
Jared W. Young, Susan B. Powell & Mark A. Geyer. (2012) Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology 62:3, pages 1381-1390.
Crossref
Crossref
T.J. Bussey, A. Holmes, L. Lyon, A.C. Mar, K.A.L. McAllister, J. Nithianantharajah, C.A. Oomen & L.M. Saksida. (2012) New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats. Neuropharmacology 62:3, pages 1191-1203.
Crossref
Crossref
Martin Sarter, Cindy Lustig & Stephan F. Taylor. (2012) Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology 62:3, pages 1544-1553.
Crossref
Crossref
Jasvinder Singh, Kamalpreet Kour & Mahesh B Jayaram. (2012) Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
J.G. Howland, B.N. Cazakoff & Y. Zhang. (2012) Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience 201, pages 184-198.
Crossref
Crossref
Leslie Citrome. (2011) Treatment-refractory schizophrenia: what is it and what has been done about it?. Neuropsychiatry 1:4, pages 325-347.
Crossref
Crossref
Salma R.I. Ribeiz, Débora P. Bassitt, Jony A. Arrais, Renata Avila, David C. Steffens & Cássio M.C. Bottino. (2010) Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder. CNS Drugs 24:4, pages 303-317.
Crossref
Crossref
Elizabeta B. Mukaetova-Ladinska, Jodie Westwood & Elaine K. Perry. 2010. The Neurochemical Basis of Autism. The Neurochemical Basis of Autism
129
161
.
Deanna M. Barch. 2010. Behavioral Neurobiology of Schizophrenia and Its Treatment. Behavioral Neurobiology of Schizophrenia and Its Treatment
43
96
.
Joseph F Goldberg & KN Roy Chengappa. (2009) Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disorders 11, pages 123-137.
Crossref
Crossref
S. Nassir Ghaemi, William S. Gilmer, Robert T. Dunn, Robert E. Hanlon, David E. Kemp, Amber D. Bauer, Lyvia Chriki, Megan M. Filkowski & Philip D. Harvey. (2009) A Double-Blind, Placebo-Controlled Pilot Study of Galantamine to Improve Cognitive Dysfunction in Minimally Symptomatic Bipolar Disorder. Journal of Clinical Psychopharmacology 29:3, pages 291-295.
Crossref
Crossref
Jared W. Young, Susan B. Powell, Victoria Risbrough, Hugh M. Marston & Mark A. Geyer. (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology & Therapeutics 122:2, pages 150-202.
Crossref
Crossref
Cherrie Galletly. (2008) Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology 202:1-3, pages 259-273.
Crossref
Crossref